What bacterial organisms are covered by levofloxacin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Levofloxacin Bacterial Coverage

Levofloxacin provides broad-spectrum coverage against both Gram-positive and Gram-negative bacteria, with particularly strong activity against respiratory pathogens including Streptococcus pneumoniae (including multidrug-resistant strains), Haemophilus influenzae, and atypical organisms, while also covering common urinary and gastrointestinal pathogens.

Gram-Positive Coverage

Levofloxacin demonstrates robust activity against key Gram-positive organisms 1:

  • Streptococcus pneumoniae - Including multidrug-resistant strains (MDRSP) resistant to penicillin, cephalosporins, macrolides, tetracyclines, and TMP-SMX
  • Streptococcus pyogenes (Group A Streptococcus)
  • Methicillin-susceptible Staphylococcus aureus (MSSA)
  • Methicillin-susceptible coagulase-negative staphylococci including S. epidermidis
  • Staphylococcus saprophyticus
  • Enterococcus faecalis

Important caveat: Levofloxacin has NO activity against methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant coagulase-negative staphylococci 1. This is a critical gap in coverage that must be considered when empirically treating skin/soft tissue infections or nosocomial pneumonia where MRSA prevalence is high.

Gram-Negative Coverage

Levofloxacin provides excellent coverage against most clinically relevant Gram-negative pathogens 1:

Enterobacteriaceae (Urinary and Intra-abdominal Pathogens)

  • Escherichia coli - Primary urinary pathogen
  • Klebsiella pneumoniae
  • Proteus mirabilis
  • Enterobacter cloacae
  • Serratia marcescens
  • Citrobacter species

Respiratory Pathogens

  • Haemophilus influenzae (including non-typeable strains)
  • Haemophilus parainfluenzae
  • Moraxella catarrhalis
  • Legionella pneumophila

Pseudomonas

  • Pseudomonas aeruginosa - Coverage exists but is less reliable than ciprofloxacin 1. When P. aeruginosa is documented or suspected (particularly in nosocomial pneumonia), combination therapy with an anti-pseudomonal β-lactam is recommended 1.

Gastrointestinal Pathogens

  • Salmonella species (including multidrug-resistant typhoid strains)
  • Shigella species
  • Yersinia pestis (plague)

Atypical Pathogen Coverage

Levofloxacin has superior activity against atypical respiratory pathogens compared to ciprofloxacin 2, 1:

  • Mycoplasma pneumoniae
  • Chlamydophila pneumoniae
  • Legionella pneumophila

This enhanced atypical coverage makes levofloxacin particularly valuable for community-acquired pneumonia, though macrolides remain preferred for isolated Mycoplasma infections 2.

Special Pathogens

  • Bacillus anthracis - FDA-approved for inhalational anthrax post-exposure prophylaxis 1
  • Yersinia pestis - FDA-approved for plague treatment and prophylaxis 1

Critical Coverage Gaps

What Levofloxacin Does NOT Cover:

  1. MRSA and methicillin-resistant coagulase-negative staphylococci - Major limitation for empiric skin/soft tissue infection treatment
  2. Anaerobes - Poor activity against Bacteroides fragilis and other anaerobes
  3. Enterococcus faecium - Only covers E. faecalis
  4. Multidrug-resistant Gram-negatives - Increasing resistance in E. coli (4-7% in recent data) and P. aeruginosa 2

Resistance Considerations

Emerging resistance is a significant concern 2:

  • Fluoroquinolone resistance in E. coli ranges from 4-7% in pediatric tertiary centers and up to 10% in some adult populations
  • Campylobacter resistance exceeds 50-80% in many regions (Taiwan, Thailand, Sweden), making levofloxacin unreliable for traveler's diarrhea from these areas 2
  • Cross-resistance exists between fluoroquinolones - organisms resistant to ciprofloxacin may also resist levofloxacin
  • Resistance rates remain low (<5%) in most pediatric Pseudomonas isolates (except cystic fibrosis patients) 2

Comparative Activity

Levofloxacin is 2-4 fold MORE active than ciprofloxacin against S. pneumoniae, S. aureus, and atypical pathogens 3, but is 2-4 fold LESS active than ciprofloxacin against most Enterobacteriaceae and P. aeruginosa 3, 4. This makes levofloxacin the preferred fluoroquinolone for respiratory infections, while ciprofloxacin remains superior for complicated urinary tract infections and Pseudomonas coverage.

References

Related Questions

For a patient prescribed levofloxacin, which concomitant medication should be stopped to prevent interference with its absorption?
What is the appropriate intravenous infusion rate for levofloxacin (Levaquin) 500 mg?
What antibiotics are not removed by dialysis?
What are the management options for patients experiencing anxiety while taking levofloxacin (Levaquin)?
Which oral antibiotics reliably cover Klebsiella pneumoniae, Citrobacter freundii, other Citrobacter species, and Proteus vulgaris?
Can the absolute neutrophil count (ANC) and absolute monocyte count (AMC) fluctuate from day to day in a patient with mild neutropenia, and if so, by how much?
Under which medical specialty is sebaceous cyst removal performed?
What is the underlying mechanism of the 6 H’s syndrome (elevated fibroblast growth factor‑23, hypophosphatemia, hyperphosphaturia, hypocalcemia, secondary hyperparathyroidism) that occurs after administration of Ferinject (ferric carboxymaltose)?
What are the differences between endovascular aneurysm repair (EVAR) and open surgical repair for abdominal aortic aneurysm (AAA)?
Can betamethasone cream be used to treat the symptoms of insect bites?
What is the recommended antibiotic regimen for salpingo‑oophoritis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.